VanEck Biotech ETF Rating → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free BBH Stock Alerts $164.06 -0.56 (-0.34%) (As of 05/10/2024 ET) Add Compare Share Share RatingsStock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestSocial MediaStock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestSocial Media VanEck Biotech ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BBH Aggregate RatingModerate Buy2.60Holdings in BBH have an aggregate rating of Moderate Buy based on 401 analyst ratings issued in the past year covering 25 companies (100.1% of the portfolio).BBH Aggregate Price Target$192.4517.31% UpsideHigh Prediction$255.27Average Prediction$192.45Low Prediction$138.46Holdings in BBH have an aggregate price target of $192.45 and a range of $138.46 to $255.27 covering 25 companies (100.1% of the portfolio).BBH Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy2 Buy rating(s)Moderate Buy16 Moderate Buy rating(s)Hold7 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by VanEck Biotech ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 BBH Holdings Export to ExcelWeightIn ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings15.02%AMGNAmgen$310.15-0.9%5 of 5 stars2.52$305.65 -1.5%21Analyst Forecast9.32%VRTXVertex Pharmaceuticals$422.78+0.9%4 of 5 stars2.48$432.18 2.2%25Earnings ReportAnalyst Forecast7.81%REGNRegeneron Pharmaceuticals$973.80+0.6%4 of 5 stars2.70$981.71 0.8%20Positive News7.45%GILDGilead Sciences$65.96+2.1%5 of 5 stars2.39$83.69 26.9%18Analyst Revision6.54%MRNAModerna$117.31-4.4%3 of 5 stars2.25$126.89 8.2%16Analyst ForecastInsider Selling4.57%ARGXargenx$374.63-2.1%3 of 5 stars2.71$528.16 41.0%21Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews Coverage4.51%BIIBBiogen$221.50-0.6%5 of 5 stars2.65$288.46 30.2%26Positive News4.49%IQVIQVIA$234.08+2.1%5 of 5 stars2.80$257.57 10.0%154.17%ILMNIllumina$110.53-0.7%5 of 5 stars2.30$164.65 49.0%20Analyst ForecastShort Interest ↓4.13%ICLRICON Public$315.39+0.1%4 of 5 stars3.00$339.44 7.6%8Short Interest ↑3.28%BGNEBeiGene$161.13-4.5%3 of 5 stars2.80$251.93 56.4%10Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap Up2.80%NBIXNeurocrine Biosciences$136.70-2.1%5 of 5 stars2.74$147.88 8.2%232.76%BMRNBioMarin Pharmaceutical$81.03-0.8%5 of 5 stars2.63$107.50 32.7%19Short Interest ↑2.53%SRPTSarepta Therapeutics$131.82-0.4%4 of 5 stars2.79$160.60 21.8%142.44%CRLCharles River Laboratories International$228.12-0.9%5 of 5 stars2.64$253.38 11.1%11Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage2.42%TECHBio-Techne$80.91+1.7%4 of 5 stars2.82$80.50 -0.5%11Positive News2.37%NTRANatera$105.29+10.2%1 of 5 stars3.00$95.13 -9.6%15Earnings ReportAnalyst DowngradeInsider SellingNews CoverageGap UpHigh Trading Volume2.26%BNTXBioNTech$91.67-0.4%2 of 5 stars2.27$118.82 29.6%11Analyst ForecastShort Interest ↑Analyst Revision2.00%QGENQiagen$43.61+0.1%4 of 5 stars2.56$50.95 16.8%91.98%EXASExact Sciences$53.51-1.2%5 of 5 stars2.92$95.40 78.3%13Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageHigh Trading Volume1.96%ALNYAlnylam Pharmaceuticals$150.47-0.6%4 of 5 stars2.59$216.19 43.7%17Analyst ForecastShort Interest ↑Analyst Revision1.77%INCYIncyte$53.06-0.8%5 of 5 stars2.47$74.93 41.2%17Short Interest ↑1.72%RGENRepligen$166.81+1.2%4 of 5 stars2.89$197.75 18.5%90.89%CRSPCRISPR Therapeutics$51.17-4.4%3 of 5 stars2.35$73.93 44.5%17Earnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionNews Coverage0.86%CYTKCytokinetics$62.10-3.0%4 of 5 stars2.87$81.60 31.4%15Earnings ReportAnalyst ForecastInsider SellingAnalyst RevisionNews Coverage This page (NASDAQ:BBH) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmithForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHow Biden has already won 2024Porter & CompanyRSVP: Charles Payne’s Cash Flow WorkshopUnstoppable ProsperityForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingGlobal crypto currency reset (41 major banks signed up)Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VanEck Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
